Topoisomerase I inhibitors for the treatment of brain tumors

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Patients with primary malignant brain tumors have a poor prognosis. Standard treatment includes surgical resection, radiation therapy and chemotherapy. Topoisomerase I inhibitors such as topotecan and irinotecan (CPT-11) represent one class of chemotherapy drugs that have been used in this disease. Recent clinical trials have shown major antitumor activity in recurrent glioblastoma when adding the antiangiogenesis drug bevacizurnab with CPT-11. The combination of targeted agents to topoisomerase I inhibitors represent a novel and promising approach. This review will summarize clinical trials with topoisomerase I inhibitors and discuss new treatment strategies for primary malignant brain tumors.

Original languageEnglish
Pages (from-to)707-716
Number of pages10
JournalExpert Review of Anticancer Therapy
Volume8
Issue number5
DOIs
StatePublished - Aug 28 2008

Fingerprint

irinotecan
Topoisomerase I Inhibitors
Brain Neoplasms
Clinical Trials
Topotecan
Drug Therapy
Glioblastoma
Pharmaceutical Preparations
Radiotherapy
Therapeutics

Keywords

  • Brain tumor
  • Gliobiastoma
  • Topoisomerase inhibitor

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Cite this

Topoisomerase I inhibitors for the treatment of brain tumors. / Feun, Lynn G; Savaraj, Niramol.

In: Expert Review of Anticancer Therapy, Vol. 8, No. 5, 28.08.2008, p. 707-716.

Research output: Contribution to journalArticle

@article{93c0c43b2e0840c3b4696806f7ba47e7,
title = "Topoisomerase I inhibitors for the treatment of brain tumors",
abstract = "Patients with primary malignant brain tumors have a poor prognosis. Standard treatment includes surgical resection, radiation therapy and chemotherapy. Topoisomerase I inhibitors such as topotecan and irinotecan (CPT-11) represent one class of chemotherapy drugs that have been used in this disease. Recent clinical trials have shown major antitumor activity in recurrent glioblastoma when adding the antiangiogenesis drug bevacizurnab with CPT-11. The combination of targeted agents to topoisomerase I inhibitors represent a novel and promising approach. This review will summarize clinical trials with topoisomerase I inhibitors and discuss new treatment strategies for primary malignant brain tumors.",
keywords = "Brain tumor, Gliobiastoma, Topoisomerase inhibitor",
author = "Feun, {Lynn G} and Niramol Savaraj",
year = "2008",
month = "8",
day = "28",
doi = "10.1586/14737140.8.5.707",
language = "English",
volume = "8",
pages = "707--716",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Topoisomerase I inhibitors for the treatment of brain tumors

AU - Feun, Lynn G

AU - Savaraj, Niramol

PY - 2008/8/28

Y1 - 2008/8/28

N2 - Patients with primary malignant brain tumors have a poor prognosis. Standard treatment includes surgical resection, radiation therapy and chemotherapy. Topoisomerase I inhibitors such as topotecan and irinotecan (CPT-11) represent one class of chemotherapy drugs that have been used in this disease. Recent clinical trials have shown major antitumor activity in recurrent glioblastoma when adding the antiangiogenesis drug bevacizurnab with CPT-11. The combination of targeted agents to topoisomerase I inhibitors represent a novel and promising approach. This review will summarize clinical trials with topoisomerase I inhibitors and discuss new treatment strategies for primary malignant brain tumors.

AB - Patients with primary malignant brain tumors have a poor prognosis. Standard treatment includes surgical resection, radiation therapy and chemotherapy. Topoisomerase I inhibitors such as topotecan and irinotecan (CPT-11) represent one class of chemotherapy drugs that have been used in this disease. Recent clinical trials have shown major antitumor activity in recurrent glioblastoma when adding the antiangiogenesis drug bevacizurnab with CPT-11. The combination of targeted agents to topoisomerase I inhibitors represent a novel and promising approach. This review will summarize clinical trials with topoisomerase I inhibitors and discuss new treatment strategies for primary malignant brain tumors.

KW - Brain tumor

KW - Gliobiastoma

KW - Topoisomerase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=45849107634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45849107634&partnerID=8YFLogxK

U2 - 10.1586/14737140.8.5.707

DO - 10.1586/14737140.8.5.707

M3 - Article

C2 - 18471044

AN - SCOPUS:45849107634

VL - 8

SP - 707

EP - 716

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 5

ER -